Table 3.
Patient outcomes of studies included for systematic review
| First author | Year of publish | Sample Size | Survivors | Survival | ICU LOS* (days) | Hospital LOS* (days) | Complications on ECMO |
|---|---|---|---|---|---|---|---|
| Mader | 2023 | 134 | 83 | 61.9% | 15 [7–29] | 20[10–40] | NR |
| Hatfield | 2023 | 118 | 78 | 66.1% | 19.5 (8–32) | 26 (11–36) | NR |
| Weidemann | 2022 | 19 | 10 | 52.6% | 37 ± 32 | NR |
Haemorrhagic 1 Cardiovascular 1 |
| Trivedi | 2022 | 7 | 5 | 71.4% | NR | NR |
Infectious 4 Renal 3 Thrombosis 1 Other(liver failure 1)1 |
| Salas | 2022 | 15 | 13 | 86.7% | NR | 48.9 ± 29.5 |
Neurologic 2 THROMBOSIS 2 |
| Lee | 2022 | 16 | 9 | 56.3% | 23.0 (12.8–52.3) | 39.5 (14.8–93.8) | 0 |
| Kim | 2022 | 21 | 16 | 76.2% | NR | 86.3 ± 50.0 | 0 |
| Eisenga | 2022 | 10 | 7 | 70.0% | NR | NR | NR |
| Brewer5 | 2022 | 12 | 10 | 83.3% | NR | 28.4 ± 6.6 | NR |
| Al-Thani | 2022 | 22 | 14 | 63.6% | 27.5 (2–62) | 39.5 (2–81) |
Renal 13 Infection 11 Thrombosis 7 Haemorrhagic 4 MOF 7 Others(thrombocytopenia 3,Mesenteric ischemia 2) 5 |
| Parker | 2021 | 13 | 5 | 38.5% | NR | NR |
Thrombosis 4 Haemorrhagic 2 |
| Henry | 2021 | 97 | 75 | 77.3% | 24 (14–34) | 29 (16–46) |
Renal 29 Neurologic 4 Infection 17 Cardiovascular 3 Limb 2 Thrombosis 17 |
| Lee | 2020 | 42 | 24 | 57.1% | 16 (7.7–24.2) | 23 (13.2–51.2) |
Renal 11 Neurologic 1 Haemorrhagic 1 Limb 1 MOF 2 Other(Decubitus ulcer 2,Cholecystitis 2) 4 |
| Huang | 2020 | 12 | 9 | 75.0% | NR | 45.5 (22–71.3) | NR |
| Guttman | 2020 | 269 | 184 | 68.4% | 22 (8–35) | 29 (12–43) |
Renal 71 Infectious 37 Neurologic 12 Cardiovascular 8 Pulmonary 88 Thrombosis 32 Other(Decubitus ulcer) 41 |
| Akhmerov | 2020 | 522 | 313 | 60.0% | 23.1 ± 20.9 | 28.5 ± 26.9 | NR |
| Kruit | 2019 | 52 | 46 | 88.5% | NR | NR |
Haemorrhagic 26 Thrombosis 21 Neurologic 3 |
| Wu | 2018 | 36 | 21 | 58.3% | NR | NR |
Haemorrhagic 12 Neurologic 3 Renal 10 |
| Strumwasser | 2018 | 7 | 2 | 28.6% | NR | NR | NR |
| Menaker | 2018 | 18 | 14 | 77.8% | 49 (18–63) | 53 (21–66) |
Haemorrhagic 6 Thrombosis 10 |
| Grant | 2018 | 19 | 9 | 47.4% | 40.5 (15.3–86) | 43.5 (15.2–102) |
Renal 10 Haemorrhagic 8 Thrombosis 5 Other(liver failure) 1 |
| Ull | 2017 | 49 | 32 | 65.3% | 24(4.8–71.7) | 46.6(2.9–197.6) |
Mechanical 22 Haemorrhagic 7 Limb 3 |
| Kim | 2017 | 9 | 8 | 88.9% | 22.0 (18.0–33.5) | 58.0 (24.0–101.0) | NR |
| Huh | 2017 | 10 | 8 | 80.0% | 24.9 ± 32.7 | 55.5 ± 56.9 |
Neurologic 3 Cardiovascular 1 MOF 1 |
| Burke | 2017 | 80 | 51 | 63.8% | 17 (5–28) | 23.5 (8.5–37.5) | NR |
| Ahmad | 2017 | 46 | 17 | 37.0% | NR | NR | NR |
| Chen | 2016 | 7 | 4 | 57.1% | 15.2 ± 7.7 | 26.8 ± 15.8 |
Renal 4 Neurologic 3 Pulmonary 1 Others (Pancreatitis)1 |
| Bosarge | 2016 | 15 | 13 | 86.7% | NR | 43.5(30.0–93.0) |
Haemorrhagic 6 Thrombosis 4 |
| Wu | 2015 | 19 | 13 | 68.4% | 16.8 ± 9.37 | NR | NR |
| Tseng | 2014 | 9 | 3 | 33.3% | NR | NR | NR |
| Guirand | 2014 | 26 | 15 | 57.7% | 36.7 ± 7.1 | 39.8 ± 7.3 |
Renal 23 Haemorrhagic 4 |
| Ried | 2013 | 26 | 21 | 80.8% | 17 (13–30) | 24 (13–44) | Mechanical 3 |
| Bonacchi | 2013 | 18 | 5 | 27.8% | NR | NR |
Mechanical 1 Limb 1 |
| Arlt | 2010 | 10 | 6 | 60.0% | NR | NR | NR |
| Huang | 2009 | 9 | 7 | 77.8% | NR | 43 (21–83.5) |
Renal 1 Neurologic 2 |
| Cordell-Smith | 2006 | 28 | 20 | 71.4% | NR | NR | NR |
ECMO Extracorporeal Membrane Oxygenation, ICU intensive care unit, LOS length of stay
*ICU LOS and Hospital LOS reported as mean ± SD, median (interquartile range) or median [range]